CMA
IONS icon

Cedar Mountain Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Cedar Mountain Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7K Hold
223
– – ﹤0.01% 372
2026
Q1 		$16.7K Buy
+223
New +$17.6K ﹤0.01% 342

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Cedar Mountain Advisors's IONS Position: Q2 2026 in Review

Cedar Mountain Advisors held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 223 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #372.

Cedar Mountain Advisors first reported a position in IONS in Q1 2026 and has held it in 2 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Cedar Mountain Advisors held 223 shares of Ionis Pharmaceuticals worth $17.7K as of Q2 2026.
  • Cedar Mountain Advisors left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #372 holding.
  • Cedar Mountain Advisors first reported a position in Ionis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.